Cargando…

Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making

Real‐world data/evidence (RWD/RWE) may provide insightful information on medicines' clinical effects to guide regulatory decisions. While its contribution has been recognized for safety monitoring and disease epidemiology across medicines' life cycles, using RWD/RWE to demonstrate efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bakker, Elisabeth, Plueschke, Kelly, Jonker, Carla J., Kurz, Xavier, Starokozhko, Viktoriia, Mol, Peter G. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099093/ https://www.ncbi.nlm.nih.gov/pubmed/36254408 http://dx.doi.org/10.1002/cpt.2766

Ejemplares similares

Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe
por: Jonker, Carla J., et al.
Publicado: (2022)

EU-funded initiatives for real world evidence: descriptive analysis of their characteristics and relevance for regulatory decision-making
por: Plueschke, Kelly, et al.
Publicado: (2018)

Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020
por: Bakker, Elisabeth, et al.
Publicado: (2023)

Marketing Authorization Applications Made to the European Medicines Agency in 2018–2019: What was the Contribution of Real‐World Evidence?
por: Flynn, Robert, et al.
Publicado: (2021)

Biomarker Qualification at the European Medicines Agency: A Review of Biomarker Qualification Procedures From 2008 to 2020
por: Bakker, Elisabeth, et al.
Publicado: (2022)

Real‐World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe
por: Cave, Alison, et al.
Publicado: (2019)

Collection of Data on Adverse Events Related to Medicinal Products: A Survey Among Registries in the ENCePP Resources Database
por: Plueschke, Kelly, et al.
Publicado: (2022)

Patient Registries: An Underused Resource for Medicines Evaluation: Operational proposals for increasing the use of patient registries in regulatory assessments
por: McGettigan, Patricia, et al.
Publicado: (2019)

Real-world evidence (RWE): A challenge for regulatory agencies discussion of the RWE conference with the network of the european medicine agencies, patients, and experts
por: Maison, Patrick, et al.
Publicado: (2022)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Real-world evidence for regulatory decision-making: updated guidance from around the world
por: Burns, Leah, et al.
Publicado: (2023)

Attention for sex in COVID-19 trials: a review of regulatory dossiers
por: de Vries, Sieta T, et al.
Publicado: (2022)

Decisions by regulatory agencies: are they evidence-based?
por: Furberg, Curt D
Publicado: (2007)

The effect of adding real-world evidence to regulatory submissions on the breadth of population indicated for rare disease medicine treatment by the European Medicines Agency
por: Jandhyala, Ravi
Publicado: (2022)

Smog, Cognition and Real-World Decision-Making
por: Chen, Xi
Publicado: (2018)

Real-world evidence enhances decision making
por: Malone, Daniel C
Publicado: (2020)

Capturing Data in Rare Disease Registries to Support Regulatory Decision Making: A Survey Study Among Industry and Other Stakeholders
por: Jonker, Carla J., et al.
Publicado: (2021)

Real‐world evidence to support regulatory decision‐making for medicines: Considerations for external control arms
por: Burcu, Mehmet, et al.
Publicado: (2020)

Transferability of real-world data across borders for regulatory and health technology assessment decision-making
por: Jaksa, Ashley, et al.
Publicado: (2022)

Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label
por: Dal-Ré, Rafael, et al.
Publicado: (2021)

Beyond this world: scientific missions of the European Space Agency
por: Calder, Nigel
Publicado: (1995)

Assessing strength of evidence for regulatory decision making in licensing: What proof do we need for observational studies of effectiveness?
por: Slattery, Jim, et al.
Publicado: (2020)

Pharmacoepidemiology Research-Real-World Evidence for Decision Making
por: Bérard, Anick
Publicado: (2021)

The Current Landscape and Emerging Applications for Real‐World Data in Diagnostics and Clinical Decision Support and its Impact on Regulatory Decision Making
por: Baumfeld Andre, Elodie, et al.
Publicado: (2022)

Developing and testing measures of reproductive decision-making agency in Nepal
por: Hinson, Laura, et al.
Publicado: (2019)

Translating Academic Drug Discovery Into Clinical Development: A Survey of the Awareness of Regulatory Support and Requirements Among Stakeholders in Europe
por: Kallio, Marko J., et al.
Publicado: (2022)

Real world data: Additional source for making clinical decisions
por: Mahajan, Rajiv
Publicado: (2015)

Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data
por: Jang, Ha Young, et al.
Publicado: (2022)

Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making
por: Németh, Bertalan, et al.
Publicado: (2023)

Agency in Contraceptive Decision-Making in Patient Care: a Psychometric Measure
por: Harper, Cynthia C., et al.
Publicado: (2022)

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2018)

Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013–2017
por: Brown, Jeremy Philip, et al.
Publicado: (2019)

Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World
por: Fernández-Garza, Luis E., et al.
Publicado: (2023)

Real-world data mining : applied business analytics and decision making
por: Delen, Dursun
Publicado: (2014)

Access to regulatory data from the European Medicines Agency: the times they are a-changing
por: Wieseler, Beate, et al.
Publicado: (2012)

Regulatory Science to 2025: An Analysis of Stakeholder Responses to the European Medicines Agency's Strategy
por: Hines, Philip A., et al.
Publicado: (2020)

Building organizational reputation in the European regulatory state: An analysis of EU agencies' communications
por: Rimkutė, Dovilė
Publicado: (2019)

When the Choice Is Ours: Context and Agency Modulate the Neural Bases of Decision-Making
por: Forstmann, Birte U., et al.
Publicado: (2008)

Patient participation in decision-making about cardiovascular preventive drugs – resistance as agency
por: Hultberg, Josabeth, et al.
Publicado: (2017)

Language policy at an abortion clinic: linguistic capital and agency in treatment decision-making
por: van Hest, Ella, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_htaoe5h6bssf5r5qmm7bp7683d